Member Info for LTbeliever

AFS 2025 tb released in next 2-3 weeks so it'll be good to hear about the Outlook too, especially those Expo trips' feedback about interest in PFAS detection.

Pls don't tell us which ones, otherwise FFX will go there and dampen all excitement :)))

Beggars cannot be choosers, Soup :)); we will get whatever Dan can get, right?

Soup, thanks, one conclusion stemming from your extract i.e. "the upfront would be likely to be in the $10-20m range. The NPV of such a deal could be in the order of £50m, assuming a 10% probability of success and a 13% WACC. This future value suggests the current fair value probably lies in the £10m to £20m range".

Upfront in GBP would be, as above, 8-16mln appx whilst the "current FV lies in 10-20mln GBP range"; this implies that most of the SP gain would flow from the upfront fee (80%) and only a small portion (20%) from the rest of the deal (milestone payments etc).

52 mln valuation (assumptions still hold, even from 2021 - pls read the Note) means 2p, NOT 10p! And 2p is the best case scenario possibly. "global deal value of between $360-450m" means over a period of time, subject to milestones etc, hence the 52mln valuation. DYOR

Dicko80, thanks for the Allenby Research Note; although from 2021, it still contains some salient points/numbers which are still valid IMO eg "Our valuation of NXP002 as a PRECLINICAL asset...gives a risk adjusted VALUATION of NFX of £52.8m".

"NFX is looking to license the asset before Phase I, in which case we would anticipate a global deal value of between $360-450m, in upfront and milestone payments, plus single digit royalties on sales, increasing in value in proportion to the stage of development of the underlying asset"

"The de-risked global value of NXP002 in IPF is £528m, which illustrates its total value potential."

"For simplicity, we look at the value of the asset as if NFX were to market the product, rather than via a licensing deal, to illustrate its worth to potential licensees. Our valuation of NXP002 as a preclinical asset using a 13% WACC gives a risk adjusted valuation of NFX of £52.8m. This assumes that a Phase I ready package for the asset is in place which is being developed over the next 12-18 months, subject to funding"

No, I mean now (in next few weeks, simultaneously with various parties) just for IPF.

Soup, in your opinion, could Dan sign more than one deals with different parties eg for different uses of NPX002? This is still unclear.

Saloon, IMO it looks like the WBuffett link refers to another stock, it's a marketing link separate from NFX's chart.

Looks like SB added another 1%? Let's see if we'll get a TR1.

MMs have no stock right now, can buy any amount you offer to sell; maybe someone has placed a big BUY order? Either to build a stake or do they have insider info? Obviously, the rest of us can only keep guessing but, 1 day before elections, this trade pattern is very unusual. MMs don't stock up unless they have a reason that will make them money, right?

Can only get a price to BUY 500 Pounds worth, or less, can't get a price beyond that.

Plus, Dan has 2% of NFX, not worth much today but if you 10-20X that, then yes it'd be worth his 15 years in NFX, IMO.

It looks like a project they are working on? ATL2?

https://www.flexfulfillment.eu/amazon-fulfillment-center-atl2-in-stone-mountain-usa/

From LinkedIn -- "Eviatar Cohen Hav Ron and Michelle Frampton-Shorey had a great visit yesterday at hashtag#Amazon’s ATL2 site in Atlanta. This visit was a strong example of what real partnership looks like in practice, with teams working closely together to support the hashtag#success of the project. We would like to express our sincere appreciation to the hashtag#ATL2 teams for their commitment and collaboration, especially Ray Griffin, ATL2 LP, for his consistent hands-on involvement and dedication throughout the process, and Aaron Brusch, Sr. Manager, E2E Solutions, for his continued support. We value this important hashtag#collaboration and look forward to the next stages of the project together."

hashtag#SupplyChainSecurity hashtag#Logistics hashtag#Partnerships hashtag#Contguard hashtag#OperationalExcellence

THaven, I agree that some posts are so blatantly PnD; however, you say that "FDA approval is about the drug, not the margin you can make on it. The margin is not attractive nor the RTO to any big pharmas. So this really could rumble on for a long time and basically could also never get to market."

How can you be so sure that no pharmas are interested? Do you have access to their RnD departments or their Board Rooms? Is Dan issuing RNSs about ongoing discussions with potential, but interested, partners just to PnD the SP? Are those investors who pumped 1mln 8 weeks ago also naive and ignorant? How can anyone be, including you, 100% certain of what's really going on?

At the end of the day, NFX doesn't need to make a drug or even a profitable drug, it just needs a p/ship and/or development agreement to get funding for NPX002 and 004 for the SP to rise materially. Is this 100% not possible?

Nice one Soup, thanks!

"The interest in the lung space confirms what BioSpace reported earlier this year in discussions with investors on hot therapeutic areas. Several named IPF as a key focus area, citing new modalities, targets and pending patent cliffs driving innovation. The global IPF market generated almost $3 billion in 2025 and is estimated to reach US nearly $7 billion by 2035."

I am sure if anyone saw that, they wouldn't share it here, they would just mortgage the house and load up!!

Just KIDDING!! :)))

Dan was seen entering AZ's offices this afternoon.

U can't BUY more than 2k worth of shares at Mkt price, but you can sell more than 7k! This morning it was the other way round.